MIST insider filings
Milestone Pharmaceuticals Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-19. Screen MIST transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 1 insider filing (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Krick Anthony J — Vice President, Finance | 1 | — | — | — |
Recent insider filings — Milestone Pharmaceuticals Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 3 | Krick Anthony J — Vice President, Finance | Holdings only — no transactions reported | EDGAR |
| 2026-06-12 | 4 | Duty Stuart — Director | Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Wills Robert James — Director | Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Saik Andrew — Director | Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Fischer Seth H. Z. — Director | Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | TOMSICEK MICHAEL JOHN — Director | Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Giles Lisa M. — Director | Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | PAPA JOSEPH C — Director | Grant/award (A): 77,000 (derivative) @ $0 | EDGAR |
| 2026-04-20 | 4 | Oliveto Joseph — President and CEO, Director | Sale (S): 36,500 @ $2.26 | EDGAR |
| 2026-02-05 | 4/A | Nelson Jeffrey Edward — Chief Operating Officer | Grant/award (A): 204,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4/A | Bharucha David — Chief Medical Officer | Grant/award (A): 204,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4/A | Hasija Amit — CFO & EVP of Corp. Development | Grant/award (A): 204,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4/A | Muller Lorenz — Chief Commercial Officer | Grant/award (A): 204,000 (derivative) @ $0 | EDGAR |
| 2026-02-05 | 4/A | Oliveto Joseph — President and CEO, Director | Grant/award (A): 679,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Nelson Jeffrey Edward — Chief Operating Officer | Grant/award (A): 204,000 (derivative) @ $0 · Grant/award (A): 136,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Bharucha David — Chief Medical Officer | Grant/award (A): 204,000 (derivative) @ $0 · Grant/award (A): 136,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Hasija Amit — CFO & EVP of Corp. Development | Grant/award (A): 204,000 (derivative) @ $0 · Grant/award (A): 136,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Muller Lorenz — Chief Commercial Officer | Grant/award (A): 204,000 (derivative) @ $0 · Grant/award (A): 136,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Oliveto Joseph — President and CEO, Director | Grant/award (A): 679,000 (derivative) @ $0 · Grant/award (A): 453,000 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Nelson Jeffrey Edward — Chief Operating Officer | Grant/award (A): 100,000 · Sale (S): 58,007 @ $2.32 · Option exercise (M): 20,100 · Sale (S): 12,245 @ $1.93 · Grant/award (A): 100,000 (derivative) @ $0 · Option exercise (M): 20,100 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Bharucha David — Chief Medical Officer | Grant/award (A): 100,000 · Sale (S): 58,007 @ $2.32 · Option exercise (M): 20,100 · Sale (S): 12,245 @ $1.93 · Grant/award (A): 100,000 (derivative) @ $0 · Option exercise (M): 20,100 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Hasija Amit — CFO & EVP of Corp. Development | Grant/award (A): 100,000 · Sale (S): 58,007 @ $2.32 · Option exercise (M): 20,100 · Sale (S): 12,245 @ $1.93 · Grant/award (A): 100,000 (derivative) @ $0 · Option exercise (M): 20,100 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Muller Lorenz — Chief Commercial Officer | Grant/award (A): 100,000 · Sale (S): 53,566 @ $2.32 · Option exercise (M): 20,100 · Sale (S): 11,180 @ $1.93 · Grant/award (A): 100,000 (derivative) @ $0 · Option exercise (M): 20,100 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Oliveto Joseph — President and CEO, Director | Grant/award (A): 280,000 · Sale (S): 133,054 @ $2.32 · Option exercise (M): 66,600 · Sale (S): 34,523 @ $1.93 · Grant/award (A): 280,000 (derivative) @ $0 · Option exercise (M): 66,600 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Oliveto Joseph — President and CEO, Director | Sale (S): 500 @ $2.25 · Sale (S): 43,000 @ $2.25 | EDGAR |
| 2025-12-11 | 4 | Muller Lorenz — Chief Commercial Officer | Gift (G): 25,000 @ $0 | EDGAR |
| 2025-07-15 | 4 | Liebert Debra K. — Director | Grant/award (A): 16,666 · Grant/award (A): 16,793 (derivative) · Grant/award (A): 16,793 (derivative) | EDGAR |
| 2025-07-15 | 4 | Hasija Amit — CFO & EVP of Corp. Development | Grant/award (A): 50,000 · Grant/award (A): 50,000 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2025-07-15 | 4 | Wills Robert James — Director | Grant/award (A): 50,000 · Grant/award (A): 50,000 (derivative) · Grant/award (A): 50,000 (derivative) | EDGAR |
| 2025-07-15 | 4 | Bharucha David — Chief Medical Officer | Grant/award (A): 53,333 · Grant/award (A): 53,333 (derivative) · Grant/award (A): 53,333 (derivative) | EDGAR |
| 2025-07-15 | 4 | Oliveto Joseph — President and CEO, Director | Grant/award (A): 66,666 · Grant/award (A): 66,666 (derivative) · Grant/award (A): 66,666 (derivative) | EDGAR |
| 2025-07-15 | 4 | Muller Lorenz — Chief Commercial Officer | Grant/award (A): 66,666 · Grant/award (A): 66,666 (derivative) · Grant/award (A): 66,666 (derivative) | EDGAR |
| 2025-07-15 | 4 | PAPA JOSEPH C — Director | Grant/award (A): 100,000 · Grant/award (A): 100,000 (derivative) · Grant/award (A): 100,000 (derivative) | EDGAR |
| 2025-06-12 | 4 | Wills Robert James — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | TOMSICEK MICHAEL JOHN — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Saik Andrew — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Giles Lisa M. — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Fischer Seth H. Z. — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Duty Stuart — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | PAPA JOSEPH C — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4 | Nelson Jeffrey Edward — Chief Operating Officer | Grant/award (A): 120,600 (derivative) @ $0 · Grant/award (A): 80,400 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4 | Muller Lorenz — Chief Commercial Officer | Grant/award (A): 120,600 (derivative) @ $0 · Grant/award (A): 80,400 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4 | Hasija Amit — CFO & EVP of Corp. Development | Grant/award (A): 120,600 (derivative) @ $0 · Grant/award (A): 80,400 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4 | Bharucha David — Chief Medical Officer | Grant/award (A): 120,600 (derivative) @ $0 · Grant/award (A): 80,400 (derivative) @ $0 | EDGAR |
| 2025-01-29 | 4 | Oliveto Joseph — President and CEO, Director | Grant/award (A): 399,600 (derivative) @ $0 · Grant/award (A): 266,400 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | PAPA JOSEPH C — Director | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2024-08-29 | 4 | Duty Stuart — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-08-29 | 4 | Giles Lisa M. — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-08-29 | 4 | Fischer Seth H. Z. — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-08-29 | 4 | Wills Robert James — Director | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Milestone Pharmaceuticals Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-28 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-09-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-15 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-20 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-26 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-13 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-01-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MIST returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs